US20090216321A1 - Prosthetic valve with selectively positioned bioactive agent - Google Patents
Prosthetic valve with selectively positioned bioactive agent Download PDFInfo
- Publication number
- US20090216321A1 US20090216321A1 US12/437,731 US43773109A US2009216321A1 US 20090216321 A1 US20090216321 A1 US 20090216321A1 US 43773109 A US43773109 A US 43773109A US 2009216321 A1 US2009216321 A1 US 2009216321A1
- Authority
- US
- United States
- Prior art keywords
- prosthetic valve
- agent
- leaflet
- fluid flow
- body vessel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
- A61F2/2418—Scaffolds therefor, e.g. support stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2475—Venous valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0008—Fixation appliances for connecting prostheses to the body
- A61F2220/0016—Fixation appliances for connecting prostheses to the body with sharp anchoring protrusions, e.g. barbs, pins, spikes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0017—Angular shapes
- A61F2230/0026—Angular shapes trapezoidal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0067—Three-dimensional shapes conical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0073—Quadric-shaped
- A61F2230/008—Quadric-shaped paraboloidal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0095—Saddle-shaped
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
Abstract
A prosthetic valve includes a support frame, a leaflet attached to the support frame, and a bioactive agent associated with the leaflet. A first free edge of the leaflet permits fluid flow through a body vessel in a first direction and substantially prevents fluid flow through the body vessel in a second, opposite direction. A second free edge of the leaflet at least partially defines an opening for permitting a controlled amount of fluid flow through the body vessel.
Description
- This application is a continuation of U.S. patent application Ser. No. 11/244,991, filed on Oct. 6, 2005, currently pending, which claims priority to U.S. Provisional Application Ser. No. 60/616,512, filed on Oct. 6, 2004. The entire disclosure of each of these related applications is hereby incorporated by reference into this disclosure.
- Medical devices that include one or more bioactive agents are disclosed. Particular embodiments of the medical devices are intraluminal valve prostheses that include one or more bioactive agents.
- Medical devices are used in the treatment of a wide variety of conditions. Bioactive agents can be associated with medical devices to provide a device that includes a particular biological effect upon implantation in a host.
- Many vessels in animal bodies transport fluids from one bodily location to another. Frequently, fluid flows in a unidirectional manner along the length of the vessel. Varying fluid pressures over time, however, can introduce a reverse flow direction in the vessel. In some vessels, such as mammalian veins, natural valves are positioned along the length of the vessel and act as one-way check valves that open to permit the flow of fluid in the desired direction and close to prevent fluid flow in a reverse direction, i.e., retrograde flow. The valves can change from an open position in response to a variety of circumstances, including changes in the cross-sectional shape of the vessel and the fluid pressure within the vessel.
- While natural valves may function for an extended time, some may lose effectiveness, which can lead to physical manifestations and pathology. For example, venous valves are susceptible to becoming insufficient due to one or more of a variety of factors. Over time, the vessel wall may stretch, affecting the ability of the valve leaflets to close. Furthermore, the leaflets may become damaged, such as by formation of thrombus and scar tissue, which may also affect the ability of the valve leaflets to close. Once valves are damaged, venous valve insufficiency may be present, which may lead to discomfort and possibly ulcers in the legs and ankles.
- Current treatments for venous valve insufficiency include the use of compression stockings that are placed around the leg of a patient in an effort to force the vessel walls radially inward to restore valve function. Surgical techniques are also employed in which valves can be bypassed, eliminated, or replaced with autologous sections of veins having competent valves.
- Minimally invasive techniques and instruments for placement of intraluminal medical devices have developed over recent years. A wide variety of treatment devices that utilize minimally invasive technology has been developed and includes stents, stent grafts, occlusion devices, infusion catheters and the like. Minimally invasive intravascular devices have especially become popular with the introduction of coronary stents to the U.S. market in the early 1990s. Coronary and peripheral stents have been proven to provide a superior means of maintaining vessel patency, and have become widely accepted in the medical community. Furthermore, the use of stents has been extended to treat aneurysms and to provide occlusion devices, among other uses.
- Recently, prosthetic valves that are implantable by minimally invasive techniques have been developed. Frequently, a graft member is attached to a support frame and provides a valve function to the device. For example, the graft member can be in the form of a leaflet that is attached to a support frame and movable between first and second positions. In a first position, the valve is open and allows fluid flow to proceed through a vessel in a first direction, and in a second position the valve is closed to prevent fluid flow in a second, opposite direction. Examples of this type of prosthetic valve are described in commonly owned U.S. Pat. No. 6,508,833 to Pavcnik for a MULTIPLE-SIDED INTRALUMINAL MEDICAL DEVICE, United States Patent Application Publication No. 2001/0039450 to Pavcnik for an IMPLANTABLE VASCULAR DEVICE, and U.S. patent application Ser. No. 10/642,372, filed on Aug. 15, 2003, each of which is hereby incorporated by reference in its entirety. In other examples of prosthetic valves, a tube that terminates in leaflets is attached to one or more support frames to form a valve. The leaflets open to permit fluid flow in a first direction in response to fluid pressure on one side of the leaflets, and close to prevent fluid flow in a second, opposite direction in response to fluid pressure on opposite sides of the leaflets. An example of this configuration is provided in U.S. Pat. No. 6,494,909 to Greenhalgh for AN ENDOVASCULAR VALVE, which is hereby incorporated by reference in its entirety.
- Medical devices that include one or more bioactive agents are disclosed. Particular embodiments of the invention relate to intraluminal valve prostheses that include one or more bioactive agents.
- An intraluminal valve prostheses according to one exemplary embodiment comprises a graft member that comprises a bioactive agent.
- Additional understanding of the invention can be obtained with review of the detailed description of exemplary embodiments, appearing below, and the appended drawings that illustrate various exemplary embodiments.
-
FIG. 1 is a perspective view of a medical device according to a first exemplary embodiment. -
FIG. 2 is a sectional view of a body vessel containing the medical device illustrated inFIG. 1 . -
FIG. 3 is a sectional view of a body vessel containing the medical device illustrated inFIG. 1 . -
FIG. 4 is a perspective view of a medical device according to a second exemplary embodiment. -
FIG. 5 is a perspective view of the medical device illustrated inFIG. 4 disposed within in a body vessel. -
FIG. 6 is a perspective view of a medical device according to a third exemplary embodiment. -
FIG. 7 is a perspective view of a medical device according to a fourth exemplary embodiment. -
FIG. 8 is a perspective view of a medical device according to a fifth exemplary embodiment. -
FIG. 9 is a perspective view of a medical device according to a sixth exemplary embodiment. -
FIG. 10 is a perspective view of a medical device according to a seventh exemplary embodiment. - The following provides a detailed description of exemplary embodiments. The description is not intended to limit the scope of the invention, or its protection, in any manner, but rather serves to enable those skilled in the art to practice the invention.
- The invention provides medical devices that can be used in a variety of applications. For example, a medical device according to the invention can be used to provide intraluminal support to a body vessel. Medical devices according to exemplary embodiments comprise prosthetic valves that can be used to regulate fluid flow through a body vessel. The prosthetic valves can be implanted in a body vessel, or in any other suitable environment, to regulate the flow of fluid. Valves according to the invention can also be implanted in ducts, canals, and other passageways in the body, as well as cavities and other suitable locations. Valves according to exemplary embodiments of the invention can be implanted in the vessels of the vasculature, such as veins, to regulate the flow of blood through the vessels.
- As used herein, the term “implanted,” and grammatically related terms, refers to the positioning of an item in a particular environment, either temporarily, semi-permanently, or permanently. The term does not require a permanent fixation of an item in a particular position.
-
FIGS. 1 through 3 illustrate a first exemplary embodiment. The medical device of this embodiment is aprosthetic valve 10 that can be used to regulate the flow of fluid through a body vessel. Thevalve 10 includes agraft member 12, which can also be referred to as a leaflet, that has abase portion 14 and avalve portion 16. Thevalve 10 also includes a means for maintaining an axial position of a portion of theleaflet 12 in a body vessel in which thevalve 10 is implanted. Abioactive agent 18 is associated with theprosthetic valve 10. As used herein, the phrase “associated with” refers to a spatial relationship between two items, such as a graft member and a bioactive agent. The phrase encompasses a spatial relationship in which one item is disposed on a surface of another, as well as a spatial relationship in which one item is disposed in a portion of another. Accordingly, in medical devices according to the invention, a bioactive agent can be disposed on a portion of the device, disposed within a portion of the device, or associated with the device in any other suitable manner. - Any suitable structure can be used as the means for maintaining an axial position of the
leaflet 12 in a body vessel, and exemplary structure is illustrated inFIGS. 1 through 3 . The specific structure chosen for any particular valve according to the invention will depend on several considerations, including the nature of the leaflet and the vessel in which the valve will be implanted. The structure need only be able to substantially maintain a position of a portion of the leaflet on an axis of a vessel in which the leaflet is implanted while fluid flows through the vessel. Examples of suitable structures for the means for maintaining an axial position include barbs, integrally formed anchors, support frames, and their equivalents. In the embodiment illustrated inFIGS. 1 through 3 , the means for maintaining an axial position comprise abarb 20 that is structurally distinct from theleaflet 12. - The
leaflet 12 comprises a section of material. Theleaflet 12 can be formed of any suitable material, and need only be biocompatible or be able to be made biocompatible and be able to perform as described herein. Theleaflet 12 advantageously can be formed of a flexible material. Examples of suitable materials for theleaflet 12 include natural materials, synthetic materials, and combinations of natural and synthetic materials. Examples of suitable natural materials include extracellular matrix (ECM) materials, such as small intestine submucosa (SIS), and other bioremodellable materials, such as bovine pericardium. Other examples of ECM materials that can be used in the medical devices of the invention include stomach submucosa, liver basement membrane, urinary bladder submucosa, tissue mucosa, and dura mater. Examples of suitable synthetic materials include polymeric materials, such as expanded polytetrafluoroethylene and polyurethane. ECM materials are particularly well-suited materials for use in theleaflet 12 at least because of their abilities to remodel and to provide a scaffold onto which cellular in-growth can occur, eventually allowing the material to remodel into a structure of host cells. Resorbable materials, such as polyglycolic acid, polylactic acid, polycaprolactone and other suitable resorbable materials can also be used, including the resorbable materials listed below. - The
leaflet 12 can have any suitable size and configuration, and the specific size and configuration chosen for the leaflet in a particular valve according to the invention will depend on several considerations, including the size, configuration, and/or nature of the vessel in which the valve will be implanted. In the embodiment illustrated inFIGS. 1 through 3 , theleaflet 12 includes afirst portion 22 having afirst width 24, and asecond portion 26 having asecond width 28. Thefirst width 24 is greater than thesecond width 28. Advantageously, thefirst portion 22 includes thevalve portion 16. Also advantageously, thesecond portion 26 includes thebase portion 14. In the illustrated embodiment, atransition region 30 is disposed between the first 22 and second 26 portions, and includes a width that tapers from thefirst width 24 to thesecond width 28. - As best illustrated in
FIGS. 2 and 3 , thebase portion 14 provides a portion of theleaflet 12 that can be anchored to awall 32 of abody vessel 34 in which thevalve 10 is implanted. When thevalve 10 is implanted in a body vessel, thebase portion 14 remains substantially static, even as fluid flows through thebody vessel 34, because thebase portion 14 is associated with a means for maintaining an axial position of a portion of theleaflet 12 in the body vessel. For example, in the illustrated embodiment, thebase portion 14 defines anopening 36.Barb 20 is partially disposed in theopening 36, with ahead 38 disposed adjacent onesurface 40 of theleaflet 12. Ananchor portion 42 of thebarb 20 is disposed external to thebody vessel 34, and abody portion 44 of thebarb 20 is disposed within theopening 36 and through thewall 32 of thebody vessel 34. Thehead 38 andanchor portion 42 of thebarb 20 can be compressed toward each other during implantation of thevalve 10. - The
barb 20 can be formed of any suitable material, and need only be biocompatible or able to be made biocompatible. Also, thebarb 20 can have any suitable size and configuration, and the specific size and configuration chosen for any particular valve according to the invention will depend on several considerations, including the nature of the vessel in which the valve is being implanted. Also, the specific material used for thebarb 20 can depend on the material used for theleaflet 12. For example, in embodiments in which theleaflet 12 comprises a bioremodellable material, such as SIS, thebarb 20 can be formed of a resorbable material. As used herein, the term “resorbable” refers to the ability of a material to be absorbed into a tissue and/or body fluid upon contact with the tissue and/or body fluid. The contact can be prolonged, and can be intermittent in nature. A number of resorbable materials are known in the art, and any suitable resorbable material can be used. Examples of suitable types of resorbable materials include resorbable homopolymers, copolymers, or blends of resorbable polymers. Specific examples of suitable resorbable materials include poly-alpha hydroxy acids such as polylactic acid, polylactide, polyglycolic acid (PGA), and polyglycolide; trimethylene carbonate; polycaprolactone; poly-beta hydroxy acids such as polyhydroxybutyrate and polyhydroxyvalerate; and other polymers such as polyphosphazines, polyorganophosphazines, polyanhydrides, polyesteramides, polyorthoesters, polyethylene oxide, polyester-ethers (e.g., polydioxanone) and polyamino acids (e.g., poly-L-glutamic acid or poly-L-lysine). There are also a number of naturally derived resorbable polymers that may be suitable, including modified polysaccharides, such as cellulose, chitin, and dextran, and modified proteins, such as fibrin and casein. - In embodiments in which the barb, or another suitable means for maintaining an axial position of the leaflet, comprises a resorbable material, the
base portion 14 of theleaflet 12, or a portion thereof, can eventually become incorporated into thewall 32 of thebody vessel 34, providing the desired anchoring function. Once thebase portion 14 is sufficiently incorporated into thevessel wall 32, additional anchoring, such as that provided by thebarb 20, may no longer be needed. If thebarb 20 is formed of a resorbable material, thebarb 20 would be eliminated gradually as the material of thebarb 20 is absorbed, allowing the incorporatedbase portion 14 to perform the anchoring function. - The
prosthetic valve 10 of this exemplary embodiment does not have a support frame, an optional element that may or may not be desirable in a particular embodiment. - As best illustrated in
FIGS. 2 and 3 , thevalve portion 16 is moveable between first and second positions when thevalve 10 is implanted in abody vessel 34. In the first position, illustrated inFIG. 2 , thevalve portion 16 is positioned within thebody vessel 34 so that anopening 46 is formed between thevessel wall 32 and thevalve portion 16. Fluid is able to flow through thebody vessel 34 at the position of thevalve 10 via theopening 46 in a first direction, represented byarrow 48. As such, theleaflet 12 can be referred to as being in an open configuration and as permitting fluid flow through thebody vessel 34 in thefirst direction 48. - In the second position, illustrated in
FIG. 3 , asurface 50 of thevalve portion 16 is disposed adjacent a portion of thewall 32 of thebody vessel 34. In this configuration, theopening 46 of the first position, described above, is substantially eliminated. Accordingly, theleaflet 12 substantially prevents fluid flow through thebody vessel 34 in a second, opposite direction, represented byarrow 52. As such, theleaflet 12 can be referred to as being in a closed configuration. - The
valve portion 16 can move between the first and second positions, i.e., between open and closed configurations, in response to a change in the direction of fluid flow through a body vessel in which thevalve 10 is implanted, such as a change from flow in thefirst direction 48 to a flow in the second,opposite direction 52. Also, thevalve portion 16 can move between the first and second positions in response to a change in fluid pressure on one or more sides of theleaflet 12. - In the embodiment illustrated in
FIGS. 1 through 3 , thebioactive agent 18 is disposed on theleaflet 12. As best illustrated inFIGS. 2 and 3 , thebioactive agent 18 can be disposed within a thickness of theleaflet 12. - Any suitable bioactive agent can be used in the invention, and the specific bioactive agent, or bioactive agents, selected for any particular medical device according to the invention will depend upon several considerations, including the desired effect and the type of treatment and/or procedure in which the medical device is being used. Examples of suitable bioactives include heparin, covalent heparin or another thrombin inhibitor, hirudin, hirulog, argatroban, D-phenylalanyl-L-poly-L-arginyl chloromethyl ketone, or another antithrombogenic agent, or mixtures thereof; urokinase, streptokinase, a tissue plasminogen activator; or another thrombolytic agent, or mixtures thereof; a fibrinolytic agent; a vasospasm inhibitor; a calcium channel blocker; a nitrate, nitric oxide, a nitric oxide promoter or another vasodilator; an antimicrobial agent or antibiotic; aspirin, ticlopidine, a glycoprotein IIb/IIIa inhibitor or another inhibitor of surface glycoprotein receptors, or another antiplatelet agent; colchicine or another antimitotic, or another microtubule inhibitor, dimethylsulfoxide (DMSO), a retinoid or another antisecretory agent; cytochalasin or another actin inhibitor; or a remodeling inhibitor; deoxyribonucleic acid, an antisense nucleotide or another agent for molecular genetic intervention; methotrexate or another antimetabolite or antiproliferative agent; paclitaxel; tamoxifen citrate, Taxol® or derivatives thereof, or other anti-cancer chemotherapeutic agents; dexamethasone, dexamethasone sodium phosphate, dexamethasone acetate or another dexamethasone derivative, or another anti-inflammatory steroid or non-steroidal anti-inflammatory agent; cyclosporin, sirolimus, or another immunosuppressive agent; tripodal (aPDGF antagonist), angiopeptin (a growth hormone antagonist), angiogenin or other growth factors, or an anti-growth factor antibody, or another growth factor antagonist; dopamine, bromocriptine mesylate, pergolide mesylate or another dopamine agonist; 60Co, 192Ir, 32P, 111In, 90Y, 99mTc or another radiotherapeutic agent; iodine-containing compounds, barium-containing compounds, gold, tantalum, platinum, tungsten or another heavy metal functioning as a radiopaque agent; a peptide, a protein, an enzyme, an extracellular matrix component, a cellular component or another biologic agent; captopril, enalapril or another angiotensin converting enzyme (ACE) inhibitor; ascorbic acid, alpha tocopherol, superoxide dismutase, deferoxamine, a 21-amino steroid (lasaroid) or another free radical scavenger, iron chelator or antioxidant; a 14C—, 3H—, 131I—, 32P— or 36S-radiolabelled form or other radiolabelled form of any of the foregoing; estrogen or another sex hormone; AZT or other antipolymerases; acyclovir; famciclovir; rimantadine hydrochloride, ganciclovir sodium or other antiviral agents; 5-aminolevulinic acid, meta-tetrahydroxyphenylchlorin, hexadecaflouoro zinc phthalocyanine, tetramethyl hematoporphyrin, rhodamine 123 or other photodynamic therapy agents; an IgG2 Kappa antibody against Pseudomonas aeruginosa exotoxin A and reactive with A431 epidermoid carcinoma cells, monoclonal antibody against the noradrenergic enzyme dopamine betahydroxylase conjugated to saporin or other antibody target therapy agents; enalapril or other prodrugs; any endothelium progenitor cell attracting, binding and/or differentiating agents, including suitable chemoattractive agents and suitable polyclonal and monoclonal antibodies; cell migration inhibiting agents, such as smooth muscle cell migration inhibitors, such as Bamimistat, prolylhydrolase inhibitors, Probacol, c-proteinase inhibitors, halofuginone, and other suitable migration inhibitors; and gene therapy agents, or a mixture of any of these.
- The
bioactive agent 18 is disposed on aportion 60 of theleaflet 12. Theportion 60 can be any suitable portion of theleaflet 12. Advantageously, theportion 60 is a portion of theleaflet 12 for which it is desirable to have the effect that thebioactive agent 18 is able to achieve within a biological system. For example, theprosthetic valve 10 illustrated inFIGS. 1 through 3 functions by moving between open and closed positions. As illustrated inFIGS. 2 and 3 , portions of theleaflet 12 makes contact with thevessel wall 32 during such movement. If theleaflet 12 comprises a material that may become temporarily or permanently adhered to or otherwise attached to thevessel wall 32 as a result of such contact, it may be desirable to protect one or more portions of theleaflet 12 during contact. Abioactive agent 18 that prevents cellular deposition, ingrowth, or proliferation can be placed on one or more portions of theleaflet 12 to achieve such protection. An antiproliferative bioactive agent, such as paclitaxel, is believed to be advantageous in this regard. - The use of a
bioactive agent 18 to protect a portion of avalve leaflet 18 is particularly advantageous for leaflets that comprise a bioreodellable material. In these embodiments, thebioactive agent 18 protects a portion of theleaflet 18 while another portion begins the remodelling process. The protectedportion 60 will begin the remodelling process as thebioactive agent 18 dissipates from theleaflet 18. This may allow for selective protection and remodelling during a critical period, such as a period following implantation. - In the embodiment illustrated in
FIGS. 1 through 3 , theportion 60 that includes thebioactive agent 18 is a portion that may contact thevessel wall 32 during valve function, such asbase portion 14. It is understood that thebioactive agent 18 can be disposed on one or more portions of a medical device without departing from the scope of the invention. -
FIGS. 4 and 5 illustrate a second exemplary embodiment. The medical device according to this embodiment is aprosthetic valve 110 for regulating fluid flow through a body vessel. Thevalve 110 includes twoleaflets support frame 116. Eachleaflet free edge 118, 120 that is not attached to thesupport frame 116. Thefree edges 118, 120 cooperatively definevalve orifice 122. Theleaflets FIG. 7 , theorifice 122 is open and allows fluid flow through thevalve 110 in a first direction, represented byarrow 174. In the second position, thefree edges 118, 120 ofleaflets orifice 122 and substantially prevent fluid flow through thevalve 110 in a second, opposite direction, represented byarrow 175. - In this embodiment, a
bioactive agent 124 is associated with eachleaflet free edge 118, 120. Thus, thebioactive agent 124 is positioned adjacent thevalve orifice 122. Abioactive agent 124 positioned in this manner may confer a desired effect onto theleaflets valve orifice 122. An antiproliferative agent, such as paclitaxel, may be used in this manner to delay remodelling of thefree edges 118, 120 ofleaflets Leaflets agent 124 first, such asbase portion 126, which may improve anchoring of thevalve 110. -
FIG. 5 illustrates theprosthetic valve 110 disposed within abody vessel 180. Thevalve 110 is shown in a closed configuration. -
FIG. 6 illustrates a third exemplary embodiment. The medical device according to this embodiment is aprosthetic valve 210 for regulating fluid flow through a body vessel. Theprosthetic valve 210 comprises a firsttubular frame member 212 and a secondtubular frame member 214 disposed circumferentially around the firsttubular frame member 212. Atubular graft member 216 is disposed about a portion of the firsttubular frame member 212 and into a space between theframe members end 217 of thegraft member 216 collapse onto the firsttubular member 212 to close anopening 219 defined by the end of thegraft member 216 and provide a valving function. - In this embodiment, the
graft member 216 defines a plurality ofopenings 218. The slits allow a controlled amount of retrograde flow through thevalve 210 when thegraft member 216 is in a closed configuration, as illustrated. This allowance of retrograde flow provides a beneficial flushing effect in the valve pocket, which may avoid pooling of fluid in the valve pocket. Abioactive agent 220 is associated with thegraft member 216 adjacent theopening 218. This positioning of the bioactive agent can provide a desired effect near theopening 218, such as a delay in remodelling of a leaflet formed of a remodellable material, as described above. - It is understood that any suitable number, size, configuration, and positioning of
openings 218 in thegraft member 216 can be used. -
FIG. 7 illustrates a fourth exemplary embodiment. The medical device according to this embodiment comprises aprosthetic valve 310. Thevalve 310 includes twoleaflets support frame 310. Eachleaflet free edge support frame 310. Thefree edges valve orifice 392. Theleaflets FIG. 7 , theorifice 392 is open and allows fluid flow through thevalve 310 in a first direction, represented byarrow 374. In the second position, thefree edges leaflets orifice 392 and substantially prevent fluid flow through the device in a second, opposite direction. Eachleaflet opening valve orifice 392 is closed. In this embodiment, each of theopenings respective leaflet more edges leaflets openings bioactive agent 398 is associated with eachleaflet respective opening -
FIG. 8 illustrates a fifth exemplary embodiment. The medical device according to this embodiment comprises aprosthetic valve 410. Theprosthetic valve 410 of this embodiment is similar to the device illustrated inFIG. 7 , except that eachopening 480, 482 is partially defined by anedge leaflet support frame 410. This configuration of theopenings 480, 482 may be advantageous if thevalve leaflets valve leaflets FIG. 7 ,free edges leaflets valve orifice 492 which opens and closes to regulate fluid flow through the device 400. Abioactive agent 498 is associated with eachleaflet free edge respective opening 480, 482. -
FIG. 9 illustrates a sixth exemplary embodiment. The medical device according to this embodiment comprises aprosthetic valve 510. Theprosthetic valve 510 is similar to thevalve 310 illustrated inFIG. 7 , except that theopening 580 that allows retrograde flow is defined by aflap 582 in theleaflet 584. A flap configuration may allow retrograde flow to proceed through the opening, and minimize or prevent any antegrade flow from proceeding through the opening. As used herein, the term “flap” refers to a section of material that is connected to or integrally formed with adjacent material at one side or end, but is free of adjacent material at another side or end. The flap is a moveable section of material that is adjacent the opening. As the flap moves, it is able to temporarily and substantially close the opening. Specific examples of suitable shapes for theflap 582 include a partial square flap, a partial triangular flap, a partial ovoid flap, and a partial teardrop-shaped flap. The actual shape chosen for the flap will depend on various factors, including the desired quantity of retrograde flow, the size and configuration of the leaflet(s) of the medical device, the desired ability of the flap to close, and the size and configuration of the vessel in which the medical device will be employed. An optional support, such as a suture that traverses theopening 580, can be added to prevent theflap 582 from inverting into theopening 580. - A
bioactive agent 590 is associated with theflap 582. This positioning of thebioactive agent 590 may provide a desired effect at theflap 582, such as a delay in remodelling as described above. Such a delay may be particularly desirable in embodiments that include a flap because it may allow the flap to open and close until the remainder of the leaflet has started or completed remodelling. Once thebioactive agent 590 has dissipated, the flap can remodel, which me result in permanent closure of the flap due to adherence to the remainder of the leaflet. -
FIG. 10 illustrates an alternative configuration of the embodiment illustrated inFIG. 9 . As illustrated inFIG. 10 , thebioactive agent 590 also can be associated with the portion of theleaflet 584 that defines theopening 580 underlying theflap 582. This positioning of thebioactive agent 590 may enhance the desired effect, such as a delay in remodeling near theopening 580. - The foregoing detailed description provides exemplary embodiments of the invention and includes the best mode for practicing the invention. These embodiments are intended only to serve as examples of the invention, and not to limit the scope of the invention, or its protection, in any manner.
Claims (21)
1. A prosthetic valve for selectively permitting fluid flow through a body vessel, said prosthetic valve comprising:
a support frame;
a leaflet attached to the support frame and having first and second free edges, the first free edge adapted to move between first and second positions and to permit said fluid flow through said body vessel in a first direction and substantially prevent said fluid flow through said body vessel in a second, opposite direction, the second free edge at least partially defining an opening for permitting a controlled amount of said fluid flow through said body vessel; and
a bioactive agent associated with the second free edge;
wherein the first free edge is free of the bioactive agent.
2. The prosthetic valve of claim 1 , wherein the second free edge entirely defines the opening.
3. The prosthetic valve of claim 1 , wherein the second free edge and a portion of the support frame define the opening.
4. The prosthetic valve of claim 1 , wherein the leaflet defines a flap capable of substantially covering the opening.
5. The prosthetic valve of claim 1 , wherein the leaflet comprises a bioremodellable material.
6. The prosthetic valve of claim 1 , wherein the leaflet comprises an extracellular matrix material.
7. The prosthetic valve of claim 1 , wherein the leaflet comprises small intestine submucosa.
8. The prosthetic valve of claim 1 , wherein the bioactive agent is adapted to prevent cellular deposition, cellular ingrowth, or cellular proliferation.
9. The prosthetic valve of claim 1 , wherein the bioactive agent comprises an antiproliferative agent.
10. The prosthetic valve of claim 9 , wherein the bioactive agent comprises paclitaxel.
11. The prosthetic valve of claim 1 , wherein the bioactive agent comprises an anti-inflammatory agent.
12. The prosthetic valve of claim 1 , wherein the bioactive agent comprises one or more of a thrombin inhibitor, an antithrombogenic agent, a thrombolytic agent, a fibrinolytic agent, an antimicrobial agent, an antiplatelet agent, an antimitotic agent, a microtubule inhibitor, an antisecretory agent, an antimetabolite, a chemotherapeutic agent, an immunosuppressive agent, a growth factor, an anti-growth factor antibody, a growth factor antagonist, a dopamine agonist, a radiotherapeutic agent, a heavy metal functioning as a radiopaque agent, a biologic agent, a angiotensin converting enzyme (ACE) inhibitor, a free radical scavenger, an iron chelator; an antioxidant, a sex hormone, an antipolymerase, an antiviral, a photodynamic therapy agent, an antibody, a prodrug, a cell migration inhibiting agent, and a gene therapy agents.
13. The prosthetic valve of claim 1 , wherein the bioactive agent comprises one or more endothelium progenitor cell attracting, binding and/or differentiating agents.
14. The prosthetic valve of claim 13 , wherein the one or more endothelium progenitor cell attracting, binding and/or differentiating agents comprises one or more of a chemoattractive agent, a polyclonal antibody, and a monoclonal antibody.
15. The prosthetic valve of claim 1 , wherein the leaflet comprises a bioremodellable material and the bioactive agent is adapted to prevent cellular deposition, cellular ingrowth, or cellular proliferation.
16. The prosthetic valve of claim 1 , wherein the leaflet comprises a bioremodellable material and the bioactive agent comprises one or more endothelium progenitor cell attracting, binding and/or differentiating agents.
17. The prosthetic valve of claim 16 , wherein the one or more endothelium progenitor cell attracting, binding and/or differentiating agents comprises one or more of a chemoattractive agent, a polyclonal antibody, and a monoclonal antibody.
18. A prosthetic valve for selectively permitting fluid flow through a body vessel, said prosthetic valve comprising:
a support frame;
a first leaflet attached to the support frame and having first and second free edges, the second free edge at least partially defining a first opening for permitting a controlled amount of said fluid flow through said body vessel;
a second leaflet attached to the support frame and having third and fourth free edges, the fourth free edge at least partially defining a second opening for permitting a controlled amount of said fluid flow through said body vessel;
the first and third free edges cooperatively defining a valve orifice adapted to open to permit said fluid flow through said body vessel in a first direction and close to substantially prevent said fluid flow through said body vessel in a second, opposite direction;
a bioactive agent associated with at least one of the second and fourth free edges;
wherein at least one of the first and third free edges is free of the bioactive agent.
19. The prosthetic valve of claim 18 , wherein the second free edge entirely defines the first opening.
20. The prosthetic valve of claim 18 , wherein the second free edge and a portion of the support frame define the first opening.
21. A prosthetic valve for selectively permitting fluid flow through a body vessel, said prosthetic valve comprising:
a support frame having first and second portions;
a first leaflet attached to the support frame and having first and second free edges, the second free edge cooperating with the first portion of the support frame to define a first opening for permitting a controlled amount of said fluid flow through said body vessel;
a second leaflet attached to the support frame and having third and fourth free edges, the fourth free edge cooperating with the second portion of the support frame to define a second opening for permitting a controlled amount of said fluid flow through said body vessel;
the first and third free edges cooperatively defining a valve orifice adapted to open to permit fluid flow through said body vessel in a first direction and close to substantially prevent fluid flow through said body vessel in a second, opposite direction;
a bioactive agent associated with at least one of the second and fourth free edges;
wherein at least one of the first and third free edges is free of the bioactive agent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/437,731 US20090216321A1 (en) | 2004-10-06 | 2009-05-08 | Prosthetic valve with selectively positioned bioactive agent |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61651204P | 2004-10-06 | 2004-10-06 | |
US11/244,991 US7544207B2 (en) | 2004-10-06 | 2005-10-06 | Medical device with bioactive agent |
US12/437,731 US20090216321A1 (en) | 2004-10-06 | 2009-05-08 | Prosthetic valve with selectively positioned bioactive agent |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/244,991 Continuation US7544207B2 (en) | 2004-10-06 | 2005-10-06 | Medical device with bioactive agent |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090216321A1 true US20090216321A1 (en) | 2009-08-27 |
Family
ID=35677273
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/244,991 Active 2026-03-31 US7544207B2 (en) | 2004-10-06 | 2005-10-06 | Medical device with bioactive agent |
US12/437,731 Abandoned US20090216321A1 (en) | 2004-10-06 | 2009-05-08 | Prosthetic valve with selectively positioned bioactive agent |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/244,991 Active 2026-03-31 US7544207B2 (en) | 2004-10-06 | 2005-10-06 | Medical device with bioactive agent |
Country Status (5)
Country | Link |
---|---|
US (2) | US7544207B2 (en) |
EP (1) | EP1814490A2 (en) |
AU (1) | AU2005294316A1 (en) |
CA (1) | CA2583938A1 (en) |
WO (1) | WO2006041972A2 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120109291A1 (en) * | 2007-02-15 | 2012-05-03 | Cook Medical Technologies Llc | Artificial Valve Prosthesis with a Free Leaflet Portion |
US10940167B2 (en) | 2012-02-10 | 2021-03-09 | Cvdevices, Llc | Methods and uses of biological tissues for various stent and other medical applications |
US10993803B2 (en) | 2011-04-01 | 2021-05-04 | W. L. Gore & Associates, Inc. | Elastomeric leaflet for prosthetic heart valves |
US11129622B2 (en) | 2015-05-14 | 2021-09-28 | W. L. Gore & Associates, Inc. | Devices and methods for occlusion of an atrial appendage |
US11173023B2 (en) | 2017-10-16 | 2021-11-16 | W. L. Gore & Associates, Inc. | Medical devices and anchors therefor |
US20210393856A1 (en) * | 2018-09-25 | 2021-12-23 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for reducing calcification of heart valves |
US11406495B2 (en) | 2013-02-11 | 2022-08-09 | Cook Medical Technologies Llc | Expandable support frame and medical device |
US11457925B2 (en) | 2011-09-16 | 2022-10-04 | W. L. Gore & Associates, Inc. | Occlusive devices |
US11911258B2 (en) | 2013-06-26 | 2024-02-27 | W. L. Gore & Associates, Inc. | Space filling devices |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6602286B1 (en) | 2000-10-26 | 2003-08-05 | Ernst Peter Strecker | Implantable valve system |
US8038708B2 (en) * | 2001-02-05 | 2011-10-18 | Cook Medical Technologies Llc | Implantable device with remodelable material and covering material |
US20070027535A1 (en) * | 2005-07-28 | 2007-02-01 | Cook Incorporated | Implantable thromboresistant valve |
US6752828B2 (en) | 2002-04-03 | 2004-06-22 | Scimed Life Systems, Inc. | Artificial valve |
US6945957B2 (en) | 2002-12-30 | 2005-09-20 | Scimed Life Systems, Inc. | Valve treatment catheter and methods |
US7717952B2 (en) * | 2003-04-24 | 2010-05-18 | Cook Incorporated | Artificial prostheses with preferred geometries |
US7625399B2 (en) | 2003-04-24 | 2009-12-01 | Cook Incorporated | Intralumenally-implantable frames |
US8221492B2 (en) * | 2003-04-24 | 2012-07-17 | Cook Medical Technologies | Artificial valve prosthesis with improved flow dynamics |
US7854761B2 (en) | 2003-12-19 | 2010-12-21 | Boston Scientific Scimed, Inc. | Methods for venous valve replacement with a catheter |
US8128681B2 (en) | 2003-12-19 | 2012-03-06 | Boston Scientific Scimed, Inc. | Venous valve apparatus, system, and method |
US7261732B2 (en) * | 2003-12-22 | 2007-08-28 | Henri Justino | Stent mounted valve |
US7566343B2 (en) | 2004-09-02 | 2009-07-28 | Boston Scientific Scimed, Inc. | Cardiac valve, system, and method |
EP1814490A2 (en) * | 2004-10-06 | 2007-08-08 | Cook Incorporated | Medical device with bioactive agent |
US7442206B2 (en) * | 2004-10-28 | 2008-10-28 | Cook Incorporated | Methods and systems for modifying vascular valves |
US20060173490A1 (en) | 2005-02-01 | 2006-08-03 | Boston Scientific Scimed, Inc. | Filter system and method |
US7854755B2 (en) | 2005-02-01 | 2010-12-21 | Boston Scientific Scimed, Inc. | Vascular catheter, system, and method |
US7780722B2 (en) | 2005-02-07 | 2010-08-24 | Boston Scientific Scimed, Inc. | Venous valve apparatus, system, and method |
US7670368B2 (en) | 2005-02-07 | 2010-03-02 | Boston Scientific Scimed, Inc. | Venous valve apparatus, system, and method |
US7867274B2 (en) | 2005-02-23 | 2011-01-11 | Boston Scientific Scimed, Inc. | Valve apparatus, system and method |
US7652372B2 (en) * | 2005-04-11 | 2010-01-26 | Intel Corporation | Microfluidic cooling of integrated circuits |
US7722666B2 (en) | 2005-04-15 | 2010-05-25 | Boston Scientific Scimed, Inc. | Valve apparatus, system and method |
US8012198B2 (en) | 2005-06-10 | 2011-09-06 | Boston Scientific Scimed, Inc. | Venous valve, system, and method |
US7569071B2 (en) | 2005-09-21 | 2009-08-04 | Boston Scientific Scimed, Inc. | Venous valve, system, and method with sinus pocket |
US7799038B2 (en) | 2006-01-20 | 2010-09-21 | Boston Scientific Scimed, Inc. | Translumenal apparatus, system, and method |
US7811316B2 (en) | 2006-05-25 | 2010-10-12 | Deep Vein Medical, Inc. | Device for regulating blood flow |
US8092517B2 (en) * | 2006-05-25 | 2012-01-10 | Deep Vein Medical, Inc. | Device for regulating blood flow |
WO2008091493A1 (en) | 2007-01-08 | 2008-07-31 | California Institute Of Technology | In-situ formation of a valve |
JP5313928B2 (en) | 2007-02-05 | 2013-10-09 | ボストン サイエンティフィック リミテッド | Percutaneous valves and systems |
US8828079B2 (en) | 2007-07-26 | 2014-09-09 | Boston Scientific Scimed, Inc. | Circulatory valve, system and method |
US8257434B2 (en) | 2007-12-18 | 2012-09-04 | Cormatrix Cardiovascular, Inc. | Prosthetic tissue valve |
US8679176B2 (en) | 2007-12-18 | 2014-03-25 | Cormatrix Cardiovascular, Inc | Prosthetic tissue valve |
US7892276B2 (en) | 2007-12-21 | 2011-02-22 | Boston Scientific Scimed, Inc. | Valve with delayed leaflet deployment |
US20100010518A1 (en) * | 2008-07-09 | 2010-01-14 | Joshua Stopek | Anastomosis Sheath And Method Of Use |
PL3000472T3 (en) * | 2009-02-18 | 2017-09-29 | Cormatrix Cardiovascular, Inc. | Compositions for preventing atrial and ventricular fibrillation |
JP2014533119A (en) | 2011-05-27 | 2014-12-11 | コーマトリックス カーディオバスキュラー, インコーポレイテッドCorMatrix Cardiovascular, Inc. | Valve conduit for extracellular matrix material and method for making the same |
US9668859B2 (en) | 2011-08-05 | 2017-06-06 | California Institute Of Technology | Percutaneous heart valve delivery systems |
US9744037B2 (en) | 2013-03-15 | 2017-08-29 | California Institute Of Technology | Handle mechanism and functionality for repositioning and retrieval of transcatheter heart valves |
EP2898920B1 (en) | 2014-01-24 | 2018-06-06 | Cook Medical Technologies LLC | Articulating balloon catheter |
WO2015200554A1 (en) | 2014-06-26 | 2015-12-30 | Boston Scientific Scimed, Inc. | Medical devices and methods to prevent bile reflux after bariatric procedures |
US10143554B2 (en) * | 2015-12-03 | 2018-12-04 | Medtronic Vascular, Inc. | Venous valve prostheses |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824049A (en) * | 1995-06-07 | 1998-10-20 | Med Institute, Inc. | Coated implantable medical device |
US20020099439A1 (en) * | 2000-09-29 | 2002-07-25 | Schwartz Robert S. | Venous valvuloplasty device and method |
US6440164B1 (en) * | 1999-10-21 | 2002-08-27 | Scimed Life Systems, Inc. | Implantable prosthetic valve |
US20020177894A1 (en) * | 2001-04-16 | 2002-11-28 | Acosta George M. | Implantable venous valve |
US6494909B2 (en) * | 2000-12-01 | 2002-12-17 | Prodesco, Inc. | Endovascular valve |
US6508833B2 (en) * | 1998-06-02 | 2003-01-21 | Cook Incorporated | Multiple-sided intraluminal medical device |
US20030018379A1 (en) * | 1996-08-13 | 2003-01-23 | Heartstent Corporation | Method and apparatus for performing coronary artery bypass surgery |
US20030083741A1 (en) * | 2001-10-26 | 2003-05-01 | Yi-Ren Woo | Valved prosthesis with porous substrate |
US20030181974A1 (en) * | 2002-03-21 | 2003-09-25 | Hua Xie | Bioprosthesis and method for suturelessly making same |
US20040047979A1 (en) * | 2002-09-11 | 2004-03-11 | Yongxing Qiu | Method for applying an LbL coating onto a medical device |
US20040059411A1 (en) * | 2000-10-26 | 2004-03-25 | Strecker Ernst Peter | Implantable valve system |
US20040093070A1 (en) * | 2002-05-10 | 2004-05-13 | Hikmat Hojeibane | Frame based unidirectional flow prosthetic implant |
US20040243219A1 (en) * | 2002-02-26 | 2004-12-02 | Harald Fischer | Venous prosthesis |
US20040249445A1 (en) * | 2002-01-31 | 2004-12-09 | Rosenthal Arthur L. | Medical device for delivering biologically active material |
US20050163818A1 (en) * | 1996-11-05 | 2005-07-28 | Hsing-Wen Sung | Drug-eluting device chemically treated with genipin |
US20050187614A1 (en) * | 2004-02-20 | 2005-08-25 | Agnew Charles W. | Prosthetic valve with spacing member |
US20060282157A1 (en) * | 2005-06-10 | 2006-12-14 | Hill Jason P | Venous valve, system, and method |
US7544207B2 (en) * | 2004-10-06 | 2009-06-09 | Cook Incorporated | Medical device with bioactive agent |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7611533B2 (en) * | 1995-06-07 | 2009-11-03 | Cook Incorporated | Coated implantable medical device |
ES2286097T7 (en) * | 2000-01-31 | 2009-11-05 | Cook Biotech, Inc | ENDOPROTESIS VALVES. |
EP2168536B1 (en) * | 2003-03-12 | 2016-04-27 | Cook Medical Technologies LLC | Prosthetic valve that permits retrograde flow |
WO2004082528A2 (en) * | 2003-03-17 | 2004-09-30 | Cook Incorporated | Vascular valve with removable support component |
-
2005
- 2005-10-06 EP EP05809812A patent/EP1814490A2/en not_active Withdrawn
- 2005-10-06 CA CA002583938A patent/CA2583938A1/en not_active Abandoned
- 2005-10-06 AU AU2005294316A patent/AU2005294316A1/en not_active Abandoned
- 2005-10-06 US US11/244,991 patent/US7544207B2/en active Active
- 2005-10-06 WO PCT/US2005/035912 patent/WO2006041972A2/en active Application Filing
-
2009
- 2009-05-08 US US12/437,731 patent/US20090216321A1/en not_active Abandoned
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824049A (en) * | 1995-06-07 | 1998-10-20 | Med Institute, Inc. | Coated implantable medical device |
US20030018379A1 (en) * | 1996-08-13 | 2003-01-23 | Heartstent Corporation | Method and apparatus for performing coronary artery bypass surgery |
US20050163818A1 (en) * | 1996-11-05 | 2005-07-28 | Hsing-Wen Sung | Drug-eluting device chemically treated with genipin |
US6508833B2 (en) * | 1998-06-02 | 2003-01-21 | Cook Incorporated | Multiple-sided intraluminal medical device |
US6440164B1 (en) * | 1999-10-21 | 2002-08-27 | Scimed Life Systems, Inc. | Implantable prosthetic valve |
US20020099439A1 (en) * | 2000-09-29 | 2002-07-25 | Schwartz Robert S. | Venous valvuloplasty device and method |
US20040059411A1 (en) * | 2000-10-26 | 2004-03-25 | Strecker Ernst Peter | Implantable valve system |
US6494909B2 (en) * | 2000-12-01 | 2002-12-17 | Prodesco, Inc. | Endovascular valve |
US20020177894A1 (en) * | 2001-04-16 | 2002-11-28 | Acosta George M. | Implantable venous valve |
US20030083741A1 (en) * | 2001-10-26 | 2003-05-01 | Yi-Ren Woo | Valved prosthesis with porous substrate |
US20040249445A1 (en) * | 2002-01-31 | 2004-12-09 | Rosenthal Arthur L. | Medical device for delivering biologically active material |
US20040243219A1 (en) * | 2002-02-26 | 2004-12-02 | Harald Fischer | Venous prosthesis |
US20030181974A1 (en) * | 2002-03-21 | 2003-09-25 | Hua Xie | Bioprosthesis and method for suturelessly making same |
US20040093070A1 (en) * | 2002-05-10 | 2004-05-13 | Hikmat Hojeibane | Frame based unidirectional flow prosthetic implant |
US20040047979A1 (en) * | 2002-09-11 | 2004-03-11 | Yongxing Qiu | Method for applying an LbL coating onto a medical device |
US20050187614A1 (en) * | 2004-02-20 | 2005-08-25 | Agnew Charles W. | Prosthetic valve with spacing member |
US7544207B2 (en) * | 2004-10-06 | 2009-06-09 | Cook Incorporated | Medical device with bioactive agent |
US20060282157A1 (en) * | 2005-06-10 | 2006-12-14 | Hill Jason P | Venous valve, system, and method |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120109291A1 (en) * | 2007-02-15 | 2012-05-03 | Cook Medical Technologies Llc | Artificial Valve Prosthesis with a Free Leaflet Portion |
US8679175B2 (en) * | 2007-02-15 | 2014-03-25 | Cook Medical Technologies Llc | Artificial valve prosthesis with a free leaflet portion |
US10993803B2 (en) | 2011-04-01 | 2021-05-04 | W. L. Gore & Associates, Inc. | Elastomeric leaflet for prosthetic heart valves |
US11457925B2 (en) | 2011-09-16 | 2022-10-04 | W. L. Gore & Associates, Inc. | Occlusive devices |
US10940167B2 (en) | 2012-02-10 | 2021-03-09 | Cvdevices, Llc | Methods and uses of biological tissues for various stent and other medical applications |
US11406495B2 (en) | 2013-02-11 | 2022-08-09 | Cook Medical Technologies Llc | Expandable support frame and medical device |
US11911258B2 (en) | 2013-06-26 | 2024-02-27 | W. L. Gore & Associates, Inc. | Space filling devices |
US11129622B2 (en) | 2015-05-14 | 2021-09-28 | W. L. Gore & Associates, Inc. | Devices and methods for occlusion of an atrial appendage |
US11173023B2 (en) | 2017-10-16 | 2021-11-16 | W. L. Gore & Associates, Inc. | Medical devices and anchors therefor |
US20210393856A1 (en) * | 2018-09-25 | 2021-12-23 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for reducing calcification of heart valves |
Also Published As
Publication number | Publication date |
---|---|
WO2006041972A3 (en) | 2006-10-26 |
US20060136044A1 (en) | 2006-06-22 |
US7544207B2 (en) | 2009-06-09 |
WO2006041972A2 (en) | 2006-04-20 |
EP1814490A2 (en) | 2007-08-08 |
CA2583938A1 (en) | 2006-04-20 |
AU2005294316A1 (en) | 2006-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7544207B2 (en) | Medical device with bioactive agent | |
US8317853B2 (en) | Prosthetic valve with external support frame | |
US7563276B2 (en) | Intraluminal medical device with cannula for controlled retrograde flow | |
US9861473B2 (en) | Valve apparatus, system and method | |
US20100114300A1 (en) | Medical device with leak path | |
US7628804B2 (en) | Prosthetic valve with vessel engaging member | |
US7361189B2 (en) | Prosthetic valve with pores | |
US7566343B2 (en) | Cardiac valve, system, and method | |
US9101468B2 (en) | Methods of reducing retrograde flow | |
US7686844B2 (en) | Prosthetic valve for implantation in a body vessel | |
CA2686665A1 (en) | Monocuspid prosthetic valve having a partial sinus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |